PLAINSBORO, N.J., Dec. 07, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) - (news) today announced that it will host an institutional investor and analyst meeting on Wednesday, December 14, 2016 from 9:30 a.m. to 1:00 p.m. (ET).
A live webcast of Integra’s management team discussing the Company’s regenerative product portfolio, technology platforms and market access will be available from 9:30 a.m. to 10:45 a.m. (ET). The webcast will be accessible through the Company’s website at http://investor.integralife.com/. The event will also consist of product demonstrations and informal clinical discussions that will not be webcast.
About Integra
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as of the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]


Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 



